- Home
- HYLN vs PRQR Comparison
HYLN vs PRQR Comparison
Compare HYLN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYLN
- PRQR
- Stock Information
- Founded
- HYLN 2018
- PRQR 2012
- Country
- HYLN United States
- PRQR Netherlands
- Employees
- HYLN N/A
- PRQR N/A
- Industry
- HYLN Construction/Ag Equipment/Trucks
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- HYLN Consumer Discretionary
- PRQR Health Care
- Exchange
- HYLN Nasdaq
- PRQR Nasdaq
- Market Cap
- HYLN 268.4M
- PRQR 232.8M
- IPO Year
- HYLN N/A
- PRQR 2014
- Fundamental
- Price
- HYLN $1.65
- PRQR $2.33
- Analyst Decision
- HYLN
- PRQR Strong Buy
- Analyst Count
- HYLN 0
- PRQR 8
- Target Price
- HYLN N/A
- PRQR $8.88
- AVG Volume (30 Days)
- HYLN 1.0M
- PRQR 360.2K
- Earning Date
- HYLN 08-12-2025
- PRQR 11-06-2025
- Dividend Yield
- HYLN N/A
- PRQR N/A
- EPS Growth
- HYLN N/A
- PRQR N/A
- EPS
- HYLN N/A
- PRQR N/A
- Revenue
- HYLN $3,513,000.00
- PRQR $20,129,184.00
- Revenue This Year
- HYLN $575.94
- PRQR N/A
- Revenue Next Year
- HYLN $255.00
- PRQR N/A
- P/E Ratio
- HYLN N/A
- PRQR N/A
- Revenue Growth
- HYLN 3559.38
- PRQR 8.65
- 52 Week Low
- HYLN $1.11
- PRQR $1.07
- 52 Week High
- HYLN $4.10
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- HYLN 50.50
- PRQR 56.68
- Support Level
- HYLN $1.58
- PRQR $2.13
- Resistance Level
- HYLN $1.74
- PRQR $2.50
- Average True Range (ATR)
- HYLN 0.11
- PRQR 0.16
- MACD
- HYLN -0.01
- PRQR 0.03
- Stochastic Oscillator
- HYLN 47.30
- PRQR 67.31
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.